Drug Trial Radar · NCT02665416
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Jan 25, 2016
Primary completion
Oct 30, 2019
Study completion Oct 30, 2019
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
SelicrelumabDrug
Selicrelumab will be provided as concentrate for solution to be administered via SC injection
VanucizumabDrug
Vanucizumab will be provided as solution to be administered via IV infusion.
BevacizumabDrug
Bevacizumab will be administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- MTD of Selicrelumab in Combination With VanucizumabTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Recommended Phase II Dose of Selicrelumab in Combination With VanucizumabTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Percentage of Participants With Adverse Events (AEs)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Part II: Clinical Activity of SC Selicrelumab in Combination with Bevacizumab as Assessed by Response Evaluation in Solid Tumors, Version 1.1 (RECIST v1.1)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Part II: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Part II: Duration of Objective Response per RECIST v1.1 CriteriaTime frame: TBaseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Part II: Percentage of Participants With Disease Control per RECIST v1.1 CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
- Part II: Progression-free Survival (PFS) per RECIST v1.1 CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California
Univ of CO Health Science Ctr
Denver, Colorado
Yale Cancer Center; Medical Oncology
New Haven, Connecticut
Dana Farber Cancer Institute
Boston, Massachusetts
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cliniques Universitaires St-Luc
Brussels, Belgium
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
Toronto, Ontario, Canada
Rigshospitalet; Onkologisk Klinik
København Ø, Denmark
Irccs Ospedale San Raffaele;Oncologia Medica
Milan, Lombardy, Italy
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
Hospital del Mar; Servicio de Oncologia
Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Valencia, Spain
ICO L'Hospitalet; Servicio de oncologia medica
L'Hospitalet de Llobregat, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.